TY - JOUR
T1 - Pre- and postoperative adjuvant therapy for locally advanced rectal cancer.
AU - McGartland, Laura P.
AU - Mulcahy, Mary F.
AU - Benson, A. B.
PY - 2004/12
Y1 - 2004/12
N2 - The conventional therapy for locally advanced rectal cancer involves surgery and adjuvant therapy. The standard adjuvant therapy is combined modality treatment, including 5-fluorouracil chemotherapy and radiation. The standard of care in terms of timing of adjuvant therapy, whether pre- or postoperative, continues to evolve, and potential advantages and disadvantages exist for both neoadjuvant and adjuvant combined modality therapy. Newer modalities of assessment, such as endoscopic ultrasound, have had an impact on more accurate staging of locally advanced rectal cancer, thus impacting the choice of therapy. Continued emphasis on improving survival, decreasing local recurrence, and minimizing treatment toxicity to improve quality of life are the goals of ongoing research in the field of rectal cancer.
AB - The conventional therapy for locally advanced rectal cancer involves surgery and adjuvant therapy. The standard adjuvant therapy is combined modality treatment, including 5-fluorouracil chemotherapy and radiation. The standard of care in terms of timing of adjuvant therapy, whether pre- or postoperative, continues to evolve, and potential advantages and disadvantages exist for both neoadjuvant and adjuvant combined modality therapy. Newer modalities of assessment, such as endoscopic ultrasound, have had an impact on more accurate staging of locally advanced rectal cancer, thus impacting the choice of therapy. Continued emphasis on improving survival, decreasing local recurrence, and minimizing treatment toxicity to improve quality of life are the goals of ongoing research in the field of rectal cancer.
UR - http://www.scopus.com/inward/record.url?scp=26944471722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26944471722&partnerID=8YFLogxK
M3 - Review article
C2 - 16166957
AN - SCOPUS:26944471722
SN - 1543-0790
VL - 2
SP - 806
EP - 814
JO - Clinical advances in hematology & oncology : H&O
JF - Clinical advances in hematology & oncology : H&O
IS - 12
ER -